Abstract
Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Keywords: Coronavirus, main protease, drug design
Current Pharmaceutical Design
Title: Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses
Volume: 12 Issue: 35
Author(s): Haitao Yang, Mark Bartlam and Zihe Rao
Affiliation:
Keywords: Coronavirus, main protease, drug design
Abstract: Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Export Options
About this article
Cite this article as:
Yang Haitao, Bartlam Mark and Rao Zihe, Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses, Current Pharmaceutical Design 2006; 12 (35) . https://dx.doi.org/10.2174/138161206779010369
DOI https://dx.doi.org/10.2174/138161206779010369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Nanoparticles as Nanocarriers for the Controlled Release of some Potential Existing Antiviral Drugs for SARS-CoV-2 Management: A Review
Coronaviruses SVM Prediction of Ligand-binding Sites in Bacterial Lipoproteins Employing Shape and Physio-chemical Descriptors
Protein & Peptide Letters Shape-based Machine Learning Models for the Potential Novel COVID-19 Protease Inhibitors Assisted by Molecular Dynamics Simulation
Current Topics in Medicinal Chemistry SARS-CoV-2: An Insight into Detection Tools
Infectious Disorders - Drug Targets Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target
Current Medicinal Chemistry Can Machine Learning and Nanotechnology Help the Fight Against the Current COVID-19 Crisis?
Current Nanoscience A Case Study: Analysis of Patents on Coronaviruses and Covid-19 for Technological Assessment and Future Research
Current Pharmaceutical Design Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence
Current Pharmaceutical Design Clarification of Interaction Mechanism of Mouse Hepatitis Virus (MHV) N and nsp3 Protein with Homology Modeling and Protein-Protein Docking Analysis
Current Computer-Aided Drug Design Potential Leads from Liquorice Against SARS-CoV-2 Main Protease using Molecular Docking Simulation Studies
Combinatorial Chemistry & High Throughput Screening Initial Remedial Action to Coronavirus in India: A Study
Current Respiratory Medicine Reviews Activity of Some Novel Chalcone Substituted 9-anilinoacridines against Coronavirus (COVID-19): A Computational Approach
Coronaviruses Impact of COVID-19 Pandemic on Cardiology Resident Training and Education
New Emirates Medical Journal The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
Current Neurovascular Research Predicting the Activity of ACE Inhibitory Peptides with a Novel Mode of Pseudo Amino Acid Composition
Protein & Peptide Letters Coronavirus Disease -2019 (COVID-19) in 2020: A Perspective Study of a Global Pandemic
Current Pharmaceutical Design A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019
Infectious Disorders - Drug Targets Coronavirus Disease (COVID-19) Pandemic: A Race Against Time
Current Topics in Medicinal Chemistry Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens
Current Respiratory Medicine Reviews Promiscuous Biological Features of Newly Emerged SARS-CoV-2 Facilitate its Unrestrained Outbreak: An Update
Coronaviruses